Natus, the US provider of medical device solutions to treat brain disorders and neural pathways, has agreed to be acquired by a subsidiary of Archimed, a French investment firm specialising in the healthcare sector. The deal is worth nearly $1.2bn.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.